| Field | Specification |
|---|---|
| Mfr No | |
| Formulation | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| UniProt # |
Scientific Background
B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF) and is involved in B cell proliferation and maturation. BCMA is preferentially expressed in mature B lymphocytes and the soluble form of BCMA can be found at higher levels in the serum of Multiple Myeloma (MM) patients. BCMA is a highly attractive target antigen for immunotherapy. BCMA, similarly to CD19, is restricted in expression to mature B cells allowing the progenitorʹs population to be spared during treatment and to replenish the patientʹs B cell population. BMCA targeting therapies include bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of MM, that resulted in promising outcomes for patients. Further studies will allow a better understanding of the role of BCMA in cancer and fine tune cancer therapy tools.
Product Description
HIV-based · VSV-G-pseudotyped · SIN=YesThe anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses transduce cells with the ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (clones VHH1 and VHH2), linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. The lentiviruses also include a puromycin selection marker.
Technical Details
| Vector Type | HIV-based, VSV-G-pseudotyped lentiviral vector |
|---|---|
| Payload / Construct | VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ |
| Target Antigen / Gene | BCMA (TNFRSF17 / CD269) |
| Signaling / Architecture | CD8 hinge & TM · 4-1BB · CD3ζ |
| Selection Marker | Puromycin |
| Reporter | None |
| Biosafety Level | BSL-2 |
| SIN Vector | Yes |
| Formulation | The lentiviruses were produced from HEK293T cells, concentrated and resuspended in DMEM. |
| Supplied As | 50 µl of anti-BCMA CAR Lentivirus at a titer ≥3x108 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment. |
| Storage | −80°C; avoid repeated freeze-thaw cycles |
| Hazardous Shipping | UN3373 |
Applications
- Positive control for anti-BCMA CAR evaluation in immune cells. Transduction optimization studies.
Biosafety & Safety
The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.
This VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ lentivirus is an HIV-based, VSV-G-pseudotyped vector, which confers broad tropism. It can transduce nearly all mammalian cell types, including primary T cells, non-dividing cells, and most established cell lines.
This product requires Biosafety Level 2 (BSL-2) facilities. Although the lentiviral particles are replication-incompetent, all local, institutional, and federal regulations must be observed. Appropriate personal protective equipment must be worn during handling.
Each lot is supplied at ≥3×10⁸ TU/ml. The exact titer value is lot-specific and is provided with each shipment. Functional titer may vary depending on the target cell type.
No. CAR expression is constitutive and does not require Cre recombinase. The CAR construct is driven by the internal promoter and will be expressed immediately after transduction into the target cells.
This lentivirus includes a Puromycin resistance gene, allowing selection of stably transduced cells by treatment with Puromycin at the appropriate concentration.
Store at −80°C immediately upon receipt. Avoid repeated freeze-thaw cycles, as viral titers decrease significantly with each cycle. For long-term storage, aliquot into single-use volumes before freezing. Short-term storage at 4°C (up to 1 week) is acceptable but may result in minor titer loss.
BioHippo offers customization and add-on services for selected products. Options may include:
- Custom formulations: Virus particles can be packaged in alternative formulations upon request (additional fees may apply).
- Custom titers: Higher-titer preparations may be available; contact us for feasibility and pricing.
- Bulk orders: Volume discounts are available for qualifying order quantities.
- Technical support: Our scientific team can assist with protocol optimization and troubleshooting.
For all customization inquiries, please use the contact form or email support@biohippo.com.
